# Arjo account plan

> Arjo is a Swedish supplier of patient mobility medical devices, rental and service, with SEK 11,000 M net sales in 2025 and about 7,000 employees.

## At a glance

Arjo AB is a Malmö-based medical device company, listed on Nasdaq Stockholm, that helps caregivers move and reposition patients, prevent pressure injuries and venous thromboembolism (VTE), and support hygiene. Its customers are public and private acute care (68% of 2025 sales) and long-term care (32%) institutions in more than 100 countries; the largest markets are the US, UK, France, Canada and Germany. In 2025, net sales were SEK 11,000 M (11,292), with organic growth of 3.4%, an adjusted EBITDA margin of 17.5% and net profit of SEK 334 M. Sales split 39% capital goods, 25% rental, 20% service and 16% disposables, and the group had an average of 6,942 employees. Carl Bennet AB is the largest shareholder, and Andréas Elgaard has been President and CEO since January 7, 2026.

## Business units

- **Europe** (FY2025 restated net sales SEK 5,172 M): Segment created in Q3 2026 from the European part of the former Global Sales segment. Q3 2026 net sales were SEK 1,348 M, up 7.4% organically, driven by rental and service, with France, Italy, Poland and the Netherlands performing well and the UK slightly weaker. It is run through two regions, South and West Europe and North and Central Europe.
- **North America** (FY2025 restated net sales SEK 4,359 M): The US and Canada; the US alone accounts for 30% of Arjo's sales and Canada 10%. Q3 2026 net sales were SEK 1,087 M, up 6.4% organically, with the US growing more than 7% on patient handling, service and diagnostics. US revenue is mostly acute care, while Canada takes 65% of revenue from long-term care and is one of Arjo's most profitable markets.
- **International** (FY2025 restated net sales SEK 1,469 M): Rest of the world including distributor markets in Eastern Europe, with Australia the largest market and India second. January–September 2026 net sales were SEK 1,192 M, up 9.3% organically on India, South Africa, Australia and New Zealand, though Q3 grew only 0.5%.

## Strategic priorities

- **SEK 350 M EBIT improvement**: Arjo commits to improve EBIT by approximately SEK 350 M versus 2025, from a more effective operating model, procurement and commercial efficiency, with effects from 2027 and full effect by mid-2029; it does not depend on future growth.
- **Win where it has the right to play**: Own and expand leadership in long-term care, strengthen and scale acute care, its largest sector, and expand selectively into new care settings such as home care.
- **Simplify to amplify**: Prune a long tail of products, narrow variations in pricing and margins, improve commercial excellence and speed to market.
- **Digital and AI-enabled care partner**: Use digital tools and AI mainly for internal processes and efficiency, and also in the offer; management notes most products are not connected today.
- **New financial targets**: Updated targets for growth, profitability and capital efficiency follow in Q1 2027; the 2026 outlook is organic growth within the 3–5% target interval.

## Latest results

In Q3 2026, net sales rose to SEK 2,849 M (2,646), an organic increase of 6.0%, led by North America and Europe and by patient handling. Gross margin rose to 43.0% (41.1), helped by a US tariff refund of approximately SEK 35 M, and adjusted EBITDA reached SEK 523 M with an 18.4% margin. Net profit fell to SEK 58 M (81) after a SEK 62 M revaluation of the Atlas Mobility and Veplas holdings, both now valued at zero. For January–September 2026, net sales were SEK 8,306 M with organic growth of 4.8% and net profit of SEK 291 M (264). Net debt/adjusted EBITDA stood at 2.2, and Arjo expects 2026 organic growth within the 3–5% interval.

## Investments and deals

- **Restructuring programme**: Restructuring costs of approximately SEK 370 M are expected, primarily over the next 18 months from Q3 2026, to fund the new operating model.
- **Rental fleet**: Net investments were SEK 177 M in Q3 2026, including SEK 76 M in the rental fleet.
- **Tasmania service acquisition**: In Q2 2026 Arjo acquired a service business in Tasmania from MD Engineering Solutions for about SEK 30 M.
- **New regional operating model**: Five regional managers joined the Management Team from July 1, 2026, and new Group Sales, Group Portfolio and Group Operations functions were set up.
- **R&D and new products**: R&D costs were SEK 303 M in 2025, 2.8% of net sales; launches included the Maxi Move 5 floor lift and the Symbliss bathing system, and FDA 510(k) clearances in fetal monitoring.

## Challenges and risks

- **Profitability below target**: The adjusted EBITDA margin was 17.5% in 2025 against a target of about 23%, and cash conversion of 79.3% missed the >80% target; the CEO said "We are not good enough."
- **US tariffs and currency**: The weaker US dollar and US tariffs weighed on 2025 gross margin; currency risk is named the most material financial risk.
- **Healthcare funding and reimbursement**: Political decisions can limit healthcare funding, as in the UK in 2025, and some markets depend on reimbursement approval.
- **Pricing pressure**: In US VTE compression the average price level has dropped significantly with tough new competition.
- **Supply chain and transport costs**: Higher material and transportation costs weighed on gross margin in 2026, and suppliers of direct materials sit in more than 50 countries.

## What leadership says

> "Arjo has promised things in the past, and we have not delivered. This time, we're going to deliver." — Andréas Elgaard, President & CEO, Capital Markets Day, Stockholm, September 24, 2026

> "The strategy is really all about a plan to put Arjo back on track" — Andréas Elgaard, President & CEO, Q3 2026 earnings call, October 22, 2026

> "With 6% organic growth in the quarter, we continue to grow and strengthen our profitability. Our focus now is on turning our strategy into results and gradually building a stronger Arjo for the future." — Andréas Elgaard, President & CEO, Interim Report January–September 2026, October 22, 2026

> "We are setting a new direction to strengthen our market position, our offering and our efficiency going forward." — Andréas Elgaard, President & CEO, Annual and Sustainability Report 2025, March 30, 2026


## Where a supplier can help

- **Procurement and cost savings**: Procurement is one of the named levers of the SEK 350 M EBIT commitment, so suppliers that lower material, component or transport costs can align with that programme.
- **Digital and AI for internal efficiency**: The ambition to become a digital and AI-enabled care partner, mainly for internal processes, opens room for software, automation and data vendors.
- **Commercial excellence tools**: The new Group Sales function and the push to narrow pricing and margin variations call for pricing, CRM and sales enablement support.
- **Logistics and supply chain**: Higher transportation costs and a new transportation management system point to needs in freight, warehousing and supply chain optimisation.
- **Portfolio rationalisation**: Pruning a long tail of products and faster speed to market create demand for product lifecycle, engineering and regulatory services.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Arjo Annual and Sustainability Report 2025](https://www.arjo.com/siteassets/01-about-us/investors/2026/ahr25/arjo_ahr25_eng.pdf)

Annual report · 2026-03-30

- Arjo is a Swedish medtech group (Nasdaq Stockholm, Mid Cap; founded 1957 in Eslöv; head office in Malmö) selling mobility solutions to acute and long-term care in more than 100 countries, with approximately 7,000 employees and five product development and production units.
- FY2025 net sales SEK 11,000 M (11,292), organic growth 3.4%; adjusted EBITDA SEK 1,922 M, margin 17.5% (18.5) against a ~23% target; EBIT SEK 675 M (893); net profit SEK 334 M (498); cash conversion 79.3%; unchanged dividend SEK 0.95.
- Segments 2025: Global Sales 57% of sales, North America 39%, Diagnostics 4%; by customer 68% acute care / 32% long-term care; by type 39% capital goods, 25% rental, 20% service, 16% disposables.
- Largest product categories: Patient handling 27% of sales, Medical beds 17%, Pressure injury prevention 16%, Hygiene 7%, VTE prevention 7%; service 20% and rental 25%. Largest markets: USA 30% of sales, UK 12%, France 11%, Canada 10%, Germany 8%.
- Profitability was hit by a weaker gross margin, mainly negative currency effects and US tariffs; the CEO also cites "internal performance shortfalls".
- Leadership change: CEO Joacim Lindoff left in January 2025, CFO Niclas Sjöswärd served as interim CEO; Andréas Elgaard (ex-CEO of ITAB Shop Concept, ex-IKEA) took office on January 7, 2026. Christofer Carlsson became CFO.
- The 2020 strategy (outcome-based programs, Arjo Insight) was slowed as customers prioritised short-term needs; "Arjo needs a new strategic direction": a new strategy and new financial targets are being defined in 2026.
- 45% of the business has circular qualities (rental, service, ReNu reprocessing, which handled almost five million products in 2025); MSCI ESG rating upgraded to AAA.
- Principal owner Carl Bennet AB (Carl Bennet is Vice Chairman and chairs the Nomination Committee); Johan Malmquist chairs the Board.

### [Arjo Interim Report January-September 2026](https://www.arjo.com/siteassets/01-about-us/investors/2026/q3-2026/arjo_q3_2026_en_final.pdf)

Interim report · 2026-10-22

- Q3 2026 (Jul-Sep) net sales SEK 2,849 M (2,646), organic growth 6.0%; gross margin 43.0% (41.1); adjusted EBITDA SEK 523 M (436), margin 18.4%; adjusted EBIT SEK 247 M (165).
- Net profit fell to SEK 58 M (81) after a SEK 62 M write-down of holdings in Atlas Mobility and Veplas (now valued at zero) in net financial items; EPS SEK 0.21 (0.30).
- A US tariff refund of about SEK 35 M helped the quarter; tariffs had a positive impact of about 1.6 points on the gross margin.
- New segment reporting from Q3: Europe (SEK 1,348 M, +7.4% organic), North America (SEK 1,087 M, +6.4%), International (SEK 414 M, +0.5%).
- Jan-Sep 2026: net sales SEK 8,306 M, organic +4.8%; EBIT SEK 601 M (494); cash conversion 69.2%; net debt/adjusted EBITDA 2.2.
- Capital Markets Day commitment: improve EBIT by approximately SEK 350 M versus 2025, driven by a more effective operating model and procurement, not by growth; full effect by mid-2029; restructuring costs about SEK 370 M, mainly over the next 18 months.
- Updated financial targets for growth, profitability and capital efficiency will be presented in Q1 2027; 2026 outlook: organic growth within 3–5%.
- Management changes: Martin Waldén (Group Sales & Group Transformation), Lisa Ekelund new CFO from early November succeeding Christofer Carlsson, Jennie Borgström EVP Group Portfolio; Tobias Kramer leaves.

### [Arjo Interim Report January-June 2026](https://www.arjo.com/siteassets/01-about-us/investors/2026/q2-2026/arjo_q2_2026_final_eng.pdf)

Interim report · 2026-07-14

- Q2 2026 net sales SEK 2,759 M (2,678), organic growth 4.7%; gross margin 42.1% (43.4); adjusted EBITDA SEK 482 M (475), margin 17.5%; EBIT SEK 211 M (174); net profit SEK 125 M (92).
- H1 2026 net sales SEK 5,456 M (5,540), organic +4.2%; adjusted EBITDA SEK 938 M (961); EBIT SEK 395 M (342); cash conversion 53.0%.
- Growth driven by patient handling (ceiling lifts, the new Maxi Move 5), medical beds and service; ReNu had its strongest quarter to date.
- Q2 by old segments: Global Sales SEK 1,634 M (+7.0% organic; France, Australia, UK back to growth), North America SEK 1,032 M (+1.2%; US up, Canada down), Diagnostics SEK 97 M (+2.4%).
- Gross margin fell on unfavourable mix, higher material and transport costs and a new transportation management system; an initial US IEEPA tariff refund of about SEK 22 M reduced COGS, with a further ~SEK 30 M claim pending.
- Five regional managers joined the Management Team from July 1 (US, Canada, South and West Europe, North and Central Europe, International); Andréas Elgaard elected to the Board.
- Acquired a service business in Tasmania (MD Engineering Solutions) for about SEK 30 M; net debt SEK 4,462 M, net debt/adjusted EBITDA 2.4.
- Outlook 2026: organic growth within 3–5%; strategy to be presented at the Capital Markets Day on September 24.

### [Arjo Q3 2026 earnings call transcript](https://stockanalysis.com/quote/sto/ARJO.B/transcripts/536880-q3-2026/)

Executive talk · Andréas Elgaard, President & CEO · 2026-10-22

- Q3 2026 call (October 22, 2026), CEO Andréas Elgaard and CFO Christofer Carlsson: 6% organic growth, led by North America and Europe; International weaker in the quarter but strong year-to-date.
- CFO: gross margin up 1.9% year-on-year; a US tariff reimbursement of approximately SEK 35 million booked against COGS; total gross margin impact from US tariffs 1.6%; patient handling capital sales drove a favourable mix, partly offset by transport costs.
- Adjusted EBIT SEK 247 million (165); excluding FX and the tariff reimbursement, adjusted EBIT SEK 195 million with a 6.8% margin (6.2%); restructuring costs SEK 41 million.
- Operating cash flow SEK 485 million; working capital days 88 (82); net debt/adjusted EBITDA 2.2x; Atlas Mobility and Veplas investments written down to zero.
- Strategy recap: "a plan to put Arjo back on track" — win in acute and long-term care, selective expansion into new care settings, "simplify to amplify" portfolio, commercial excellence, "digital and an AI-enabled care partner".
- SEK 350 million EBIT improvement by mid-2029 from the operating model, cost structure, procurement and commercial excellence; further levers: portfolio and supply chain optimisation, capital efficiency, organic growth and M&A; new financial targets in Q1 2027.
- Q&A: patient handling drives the quarter; flu season "can really make or break the fourth quarter".

### [Arjo Capital Markets Day 2026 transcript](https://stockanalysis.com/quote/sto/ARJO.B/transcripts/700760-cmd-2026/)

Executive talk · Andréas Elgaard, President & CEO · 2026-09-24

- Capital Markets Day, Stockholm, September 24, 2026: CEO Andréas Elgaard presents the new strategy, with US marketing VP Jessica Shatzer and Canada sales and marketing VP Jim Findlater.
- Commitment: SEK 350 million EBIT improvement versus 2025 "within the next 30 to 36 months", the vast majority within 24 months; not fuelled by sales growth; restructuring of SEK 370 million, mostly P&L and cash, largely in 2027.
- Candid diagnosis: "We are not good enough"; the outcome-based ambitions "never really materialized"; growth targets met but cash flow and EBITDA margin missed; "Arjo has promised things in the past, and we have not delivered."
- Strategy in three buckets: "Win where we have the right to play" (long-term care leadership, scale in acute care, selective new care settings such as home care), "simplify to amplify" (portfolio pruning, pricing and commercial excellence, digital/AI), "working better together" (performance culture).
- New operating model: five regions (US, Canada, South and West Europe, North and Central Europe, International) reporting to the CEO, plus Group Sales, Group Portfolio and Group Operations functions; procurement a major lever.
- US: acute care leadership, 850 employees, 63 service centers; only about 3,000 of 16,000 nursing homes reached; ReNu reprocessing to expand. Canada: 65% of revenue in long-term care, +9% revenue CAGR 2021-2025, 22 consecutive growth quarters.
- US VTE (compression) prices dropped significantly under new competition, now "very close to the bottom"; more focus on bottom line and capital efficiency; new financial targets in Q1 2027.

## Questions about Arjo

### What does Arjo do?

Arjo supplies medical devices and solutions for patient mobility: patient handling lifts, medical beds, pressure injury prevention surfaces, hygiene systems and VTE prevention, sold, rented and serviced for acute and long-term care providers in more than 100 countries.

### What is Arjo's revenue?

Net sales were SEK 11,000 M in 2025 (11,292), with organic growth of 3.4%. For January–September 2026 net sales were SEK 8,306 M, up 4.8% organically.

### How many employees does Arjo have?

About 7,000, with an average of 6,942 in 2025.

### Who is Arjo's CEO?

Andréas Elgaard has been President and CEO since January 7, 2026; Johan Malmquist chairs the Board.

### What is Arjo's strategy?

A strategy presented in September 2026 focuses on long-term and acute care, simplifying the portfolio and becoming a digital and AI-enabled care partner, with a commitment to improve EBIT by approximately SEK 350 M versus 2025 by mid-2029.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
